Results 211 to 220 of about 2,176,861 (324)

Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris (n = 16) or pemphigus foliaceus (n = 8) received rituximab as part of routine ...
Pokphazz Christjaroon   +4 more
wiley   +1 more source

Rectal Neuroendocrine Tumor Presenting as Refractory Chronic Pruritus Ani: A Case Report. [PDF]

open access: yesCase Rep Gastroenterol
Tran TM   +6 more
europepmc   +1 more source

Acute Cutaneous Kava Toxicity: A Multicentre Case Series From South Australia

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Kava (piper methysticum) is a traditional beverage of Pacific Island communities which in 2021, re‐entered the Australian market, primarily promoted as an anxiolytic ‘wellness’ product. Emerging cases of acute kava toxicity have occurred since, characterised by a distinctive cutaneous morphology, with or without systemic manifestations.
Zoe Lee   +3 more
wiley   +1 more source

Knowledge, Attitudes, and Practices of Dermatologists on Chronic Pruritus and Its Management. [PDF]

open access: yesCureus
Talwar A   +8 more
europepmc   +1 more source

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

open access: yesAllergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan   +5 more
wiley   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

open access: yesAllergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy